Axsome stockholders approve all four proposals at 2025 annual meeting

Axsome Therapeutics, Inc.

Elected Roger A. Jeffs as Class I director with 27.3M votes for, 8.1M withheld.
Approved 2025 Long-Term Incentive Plan with 26.4M for, 8.9M against.
Ratified Deloitte & Touche as auditor for FY2025 with 40.8M for, 225.7K against.
Advisory say-on-pay passed with 34.8M for, 528.2K against.
Approximately 84% of shares (41.4M of 49.2M) represented at meeting.

item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.